Freshworks Inc vs Smith & Nephew plc — how do they compare? Freshworks Inc trades at $10.75 (market cap $2.93B), while Smith & Nephew plc trades at $31.3 (market cap $12.81B). The key difference: Smith & Nephew plc is far larger — about 4.4× Freshworks Inc's market cap, and Smith & Nephew plc pays a 2.54% dividend while Freshworks Inc pays none. Which is the better fit depends on your goals.
| FRSH | SNN | |
|---|---|---|
Market Cap | $2.93B | $12.81B |
Sector | Technology | Health |
52-Week High | $14.77 | $38.70 |
52-Week Low | $6.88 | $28.73 |
Enterprise Value | $2.19B | $15.58B |
Dividend Yield | — | 2.54% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Smith & Nephew (SNN) trades at $29.83, down 4.02% today, with a bearish technical signal. The company reported revenue of $5.81 billion in 2024, with net income of $412 million, showing improved profitability. Recent news highlights product launches in robotics and wound care, supported by a $500 million share buyback. Analyst consensus is mixed, with 27% buy ratings but 68% hold, reflecting cautious optimism amid earnings volatility.
Outlook is balanced: strong free cash flow and innovation in medical technology offer growth potential, but near-term risks include competitive pressures and debt levels. The stock's valuation at a P/E of 21.51 is reasonable if earnings growth sustains, yet technical weakness suggests caution. Investors should weigh solid fundamentals against market sentiment and execution risks.
Trailing returns across standard periods
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →